![SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/JA18039graphic1.gif)
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com
![SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire](https://mms.businesswire.com/media/20191219005272/en/764047/4/WebReady480.jpg)
SPRAVATO®▽ (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder | Business Wire
![Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/appi.ajp.2019.19020172/asset/images/medium/appi.ajp.2019.19020172f1.gif)
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | American Journal of Psychiatry
![SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/JA18039graphic2-174x300.jpg)
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com
![Esketamine Nasal Spray Effective Against Depression | Aktuelles aus der Goethe-Universität Frankfurt Esketamine Nasal Spray Effective Against Depression | Aktuelles aus der Goethe-Universität Frankfurt](https://aktuelles.uni-frankfurt.de/wp-content/uploads/2023/10/beitragsbild_esketamin-nasenspray-jpg.webp)
Esketamine Nasal Spray Effective Against Depression | Aktuelles aus der Goethe-Universität Frankfurt
![Esketamine Spravato Nasal Spray UK Delivery. at Rs 15000/box | Spravato in Ghaziabad | ID: 2853349965697 Esketamine Spravato Nasal Spray UK Delivery. at Rs 15000/box | Spravato in Ghaziabad | ID: 2853349965697](http://5.imimg.com/data5/SELLER/Default/2024/2/382579817/NY/NI/CA/83839059/esketamine-spravato-nasal-spray-uk-delivery.jpg)